Click Therapeutics is working with Invidior to develop new prescription digital therapeutics for substance misuse. The two companies will begin with Opioid Use Disorder (OUD). Developing a new mobile application, CT-102, the two companies aim to close major gaps in OUD treatment such as access to high-quality personalised psychosocial treatment.

Designed to work alongside pharmacotherapy, CT-102 will combine evidence-based behavioural therapy with tailored neuromodulatory interventions using Click’s AI-enabled platform to deliver personalised care to each patient. The collaboration will build on Indivior’s expertise in the commercialisation of innovative treatments for substance use disorders and Click Therapeutics’ substantial real-world experience engaging patients seeking help with addiction.

Click will lead development with an iterative, patient-centric and evidence-based approach that leverages the company’s end-to-end development capabilities and proprietary technology platform. This phased process is designed to ensure CT-102 will be launched as a best-in-class therapy supported by compelling evidence that will drive broad access and adoption. These efforts will start with a preliminary exploration phase to explore and define the product scope that will best match the needs of patients, providers and payers. More information will be available following completion of the exploration phase in 2024.

This is the fourth major co-development and commercialisation collaboration to be announced that is based on Click Therapeutics’ clinically validated platform. Under the terms of the collaboration agreement, Click Therapeutics will be responsible for all technical and clinical development activities, as well as regulatory filings and technical services through commercialisation. In return, Indivior will receive a global license to commercialise CT-102. Click Therapeutics will receive upfront license and early development payments, and is eligible to receive additional regulatory and commercial milestones plus double-digit royalties on global sales. In addition, there is an opportunity for a higher total deal value based on the potential development of additional products in the future.

Click therapeutics develops FDA regulated digital prescription treatments for unmet medical needs. Delivered a smartphone apps, click digital therapeutics address a range of areas including psychiatry, neurology, oncology, immunology, and cardiometabolic diseases.